Anbio Biotechnology (NNNN) Total liabilities 2023–2025
Anbio Biotechnology (NNNN) total liabilities at each fiscal year-end, per SEC filings.
$87,836FY2025 · since FY2023: $993,060 → $87,836
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $87,836 | -94.9% |
| FY2024 | $1.7M | +74.2% |
| FY2023 | $993,060 | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More NNNN financial trends
NNNN RevenueNNNN Net incomeNNNN Net marginNNNN Gross profitNNNN Gross marginNNNN Operating incomeNNNN Operating marginNNNN Operating cash flowNNNN Free cash flowNNNN Capital expendituresNNNN Return on equityNNNN Stock buybacksNNNN Dividends paidNNNN Total assetsNNNN Shareholders’ equityNNNN overview →